N
CTKB icon

Numerai’s Cytek Biosciences CTKB Stock Holding History

Numerai’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$706K Buy
159,465
+47,005
+42% +$201K 0.06% 486
2026
Q1 		$491K Sell
112,460
-74,304
-40% -$351K 0.05% 523
2025
Q4 		$943K Buy
186,764
+80,269
+75% +$373K 0.11% 258
2025
Q3 		$370K Sell
106,495
-315,823
-75% -$1.19M 0.05% 396
2025
Q2 		$1.44M Buy
+422,318
New +$1.41M 0.21% 142

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Numerai's CTKB Position: Q2 2026 in Review

Numerai increased its Cytek Biosciences (CTKB) stake by 42% in Q2 2026, buying an estimated $201K and bringing the position to 159,465 shares worth $706K. The position accounts for 0.06% of the portfolio, ranked #486.

Numerai first reported a position in CTKB in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.44M in Q2 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Numerai held 159,465 shares of Cytek Biosciences worth $706K as of Q2 2026.
  • Numerai bought 47,005 Cytek Biosciences shares in Q2 2026, an estimated $201K.
  • Cytek Biosciences made up 0.06% of Numerai's portfolio in Q2 2026, its #486 holding.
  • Numerai first reported a position in Cytek Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Numerai's Cytek Biosciences position peaked at $1.44M in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Numerai's 13F filing for Q2 2026, filed 14 Aug 2026.